Max Healthcare Institute’s board of directors has approved several key resolutions during its meeting held on 21 May 2026. Among the significant decisions, the board recommended a final dividend of ₹2 per equity share for the financial year 2025-26. This dividend, representing 20% of the face value of ₹10 per share, is subject to approval at the upcoming Annual General Meeting (AGM) and will be distributed within 30 days post-AGM.

The board also approved the audited financial results for the fourth quarter and financial year ending 31 March 2026. The financial results were audited by M/s. S.R. Batliboi & Co. LLP, Chartered Accountants, and were recommended by the Audit Committee. The auditor’s report, which accompanies the financial results, was issued with an unmodified opinion.

In addition to financial matters, the board approved the re-appointment of M/s. as Cost Auditors for the financial year 2026-27. This decision follows the recommendation of the Audit Committee.

The board also considered and approved the re-classification request from , seeking to move from ‘Promoter Group’ to ‘Public’ category. This re-classification is contingent upon receiving approval and a no-objection letter from the relevant stock exchanges.

Another significant approval was granted for the construction of Phase-I of the Max Super Specialty Hospital at Shaheed Path, Lucknow. The hospital, to be built on a 5-acre land parcel owned by the company, will have a capacity of approximately 712 census beds.

Further, the board approved the shifting of the company’s registered office from Mumbai, Maharashtra to Gurugram, Haryana, pending approval from members at the forthcoming AGM and other regulatory authorities.

The board also re-appointed Mr. as a Non-Executive and Non-Independent Director for a term of three years, effective from 1 October 2026 to 30 September 2029. Mr. Bhatnagar’s re-appointment is subject to member approval at the AGM.

The board meeting commenced at 12:07 PM and concluded at 3:44 PM. The resolutions and decisions will be available on the company’s official website.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).